Sign In
Buy LNTH
$100.25
+3.95 (+4.10%)
At Close: Jun 03, 2026
BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fig
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
08:30am, Wednesday, 23'rd Oct 2024
BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesda
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Comple
Lantheus Appoints Julie Eastland as New Board Member
08:30am, Thursday, 05'th Sep 2024
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fi
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
08:30am, Wednesday, 28'th Aug 2024
BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fig
Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
03:32pm, Monday, 12'th Aug 2024
PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its onc
13 stocks to consider if you're able to brave recession fears
07:15am, Monday, 12'th Aug 2024
Now that stock investors are beginning to realize that a recession isn't on the way, the U.S. market will get back to doing what is up to before the August swoon: showing strength beyond the Magnifice
Lantheus Reports Second Quarter 2024 Financial Results
07:00am, Wednesday, 31'st Jul 2024
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
08:30am, Wednesday, 17'th Jul 2024
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesda
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease
08:30am, Monday, 15'th Jul 2024
Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities
Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
12:32pm, Wednesday, 10'th Jul 2024
BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fig
Why Lantheus Holdings Stock Is Skyrocketing Today
11:57am, Wednesday, 10'th Jul 2024
Medicare will likely soon change how it pays for diagnostic radiopharmaceuticals. Lantheus should be a big winner from this reimbursement change.
Lantheus Stock Gets A Radioactive Surge On Medicare Proposal
10:19am, Wednesday, 10'th Jul 2024
Lantheus stock rocketed to a 13-month high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics.
Lantheus Appoints Jamie Spaeth as Chief People Officer
08:30am, Monday, 08'th Jul 2024
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fi
Deal Further Strengthens Lantheus' Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer Deal Further Strengthens Lantheus' Prostate Cancer Portfolio and Expands Pipeline to Include
